Downs J, Andriole V T, Ryan J L
Antimicrob Agents Chemother. 1982 Apr;21(4):670-2. doi: 10.1128/AAC.21.4.670.
MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. This new agent was more active than any of the other antibiotics tested, which included carbenicillin, ampicillin, cephalexin, tetracycline, trimethoprim, trimethoprim-sulfamethoxazole, and nalidixic acid. Gentamicin-resistant P. aeruginosa were highly sensitive to MK-0366, with a 90% minimal inhibitory concentration of 0.8 microgram/ml. Serratia strains were the most resistant organisms, with a 90% minimal inhibitory concentration of 3.1 micrograms/ml. These results suggest that clinical trials should be designed to investigate the clinical usefulness of this new drug in urinary infections.
萘啶酸的一种新衍生物MK-0366，针对250种尿路病原体进行了测试，这些病原体包括大肠杆菌、粘质沙雷氏菌和铜绿假单胞菌。这种新药物比所测试的其他任何抗生素都更具活性，所测试的其他抗生素包括羧苄青霉素、氨苄青霉素、头孢氨苄、四环素、甲氧苄啶、甲氧苄啶-磺胺甲恶唑和萘啶酸。耐庆大霉素的铜绿假单胞菌对MK-0366高度敏感，90%的最低抑菌浓度为0.8微克/毫升。沙雷氏菌菌株是最具耐药性的微生物，90%的最低抑菌浓度为3.1微克/毫升。这些结果表明，应设计临床试验来研究这种新药在尿路感染中的临床效用。
